
United Therapeutics terminates oral pulmonary arterial hypertension drug following Phase 3 failure
pharmafile | April 9, 2019 | News story | Manufacturing and Production, Research and Development |Â Â Tyvaso, United Therapeutics, pharma, pulmonary arterial hypertensionÂ
United Therapeutics has revealed in a short announcement that, because its pulmonary arterial hypertension (PAH) therapy failed to meet its primary endpoint at Phase 3, it has decided to discontinue all further development of the product.
The company sought to prove the efficacy of oral esuberaprost tablets when added to its inhaled therapy Tyvaso (treprostinil) compared to Tyvaso alone. However, it was found that esuberaprost failed to delay time until first clinical worsening event such as death or hospitalisation from disease worsening, falling short of the trial’s primary endpoint.
Secondary endpoints included six-minute walking distance, WHO functional class and Borg dyspnoea score.
United Therapeutics is now disadvantaged in the PAH space, after the launch by Sandoz of the first generic version of the company’s own injectable treprostinil therapy Remodulin in March.
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …






